首页> Clinical cancer research : an official journal of the American Association for Cancer Research> A B7-H4-Targeting Antibody-Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression.

A B7-H4-Targeting Antibody-Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression.

导出 OA

翻译打印收藏纠错

第一作者： Sarah B,Gitto

第一单位： Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

作者： Sarah B,Gitto ^[1] ; Margaret,Whicker ^[2] ; Gareth,Davies ^[3] ; Sushil,Kumar ^[2] ; Krista,Kinneer ^[4] ; Haineng,Xu ^[2] ; Arthur,Lewis ^[3] ; Srinivas,Mamidi ^[3] ; Sergey,Medvedev ^[2] ; Hyoung,Kim ^[2] ; Judith,Anderton ^[3] ; E Jessica,Tang ^[5] ; Benjamin,Ferman ^[2] ; Steven,Coats ^[4] ; Robert W,Wilkinson ^[3] ; Eric,Brown ^[5] ; Daniel J,Powell ^[6] ; Fiona,Simpkins ^[2]

作者单位： Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. ^[1] Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Penn Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, Pennsylvania. ^[2] AstraZeneca, Cambridge, United Kingdom. ^[3] AstraZeneca, Gaithersburg, Maryland. ^[4] Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. ^[5] Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.;Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Penn Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, Pennsylvania. ^[6]